Back to list

Journal publications


  • Clinical Experience with BIAsp 30: Results from the Philippine Cohort of the Global A1chieve Study Mary Anne Lim-Abrahan, Anand B Jain, Susan Yu-Gan, Leorino M. Sobrepena, Veronica A. Racho
    Key findings: Safety, effectiveness and health-related quality of life were assessed in 1,252 subjects from the Philippine cohort of the A1chieve study who were treated with the premixed insulin analogue biphasic insulin aspart 30 (BIAsp 30). This subset analysis of the study showed that administration of BIAsp 30 among Filipino patients (both insulin-naïve and prior insulin users) improved glycemic control without concomitant risk of hypoglycemia or weight gain. Other findings at the end of the study (24 weeks) include reductions in systolic blood pressure, total cholesterol, LDL cholesterol and triglycerides in the treated subjects.

    Philippine Journal of Internal Medicine. 2014;52(3):1-10

  • Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs PD Home, C Shen, MI Hasan, ZA Latif, JW Chen, G González Gálvez
    Key findings: Predictor and explanatory factors of change in HbA1c were studied using data from the large observational A1chieve study. Data analyses showed that the factor explaining most of the variance in HbA1c change is baseline HbA1c level, with each increase of 1.0%-units (11 mmol/mol) providing a 0.7-0.8%-units (8-9 mmol/mol) greater fall. Other factors do not explain much of the remaining variance, even when including all end-of-trial measures.

    Diabetes Care. May 2014 37;5:1237-1245

  • Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A1chieve study Chen Liming, Xing Xiaoyan, Lei Minxiang, Liu Jie, Shi Yongquan, Li Pengqiu, Qin Guijun, Li Chengjiang, Li Yukun, Wang Qing, Gao Tianshu, Hu Ling, Wang Yangwei, Yang Wenying
    Key findings: In a subgroup analysis from the A1chieve study of 4,100 Chinese patients with type 2 diabetes who were poorly controlled on oral glucose-lowering drugs (OGLDs), treatment with biphasic insulin aspart 30 alone or in combination with OGLDs was shown to improve glycemic control with low risk of hypoglycemia.

    Chinese Medical Journal. 2014;127(2):208-212

  • Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with basal insulin: findings from the multinational, non-interventional A1chieve study Issam Hajjaji, Siddharth Shah, Yuxiu Li, Vinay Prusty, Youcef Benabbas, Philip D. Home
    Key findings: In a sub-analysis of the A1chieve study, insulin-naïve and insulin-experienced people with T2DM in routine clinical care starting aspart alone at baseline and continuing aspart alone, changing to biphasic insulin aspart 30 (aspart premix) or adding a basal insulin by study end, were included. Findings of this sub-analysis were that insulin aspart therapy was well tolerated and was associated with improved glucose control over 24 weeks in people with T2DM.

    Diabetes Therapy. June 2014;5(1):113-26

  • Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the A1chieve study Mohammed E. Khamseh, Vinay Prusty, Zafar Latif, Guillermo Gonzalez-Galvez, Guillermo Dieuzeide, Alexey Zilov
    Key findings: In this sub-analysis of the A1chieve study, insulin detemir therapy was associated with significant improvements in glycemic parameters, irrespective of baseline BMI status, and also induced weight loss in overweight and obese patients with T2DM. The initiation of insulin detemir therapy was well-tolerated in all patient subgroups, stratified by baseline BMI intervals, with only 4 serious adverse drug reactions reported in the entire cohort of 10,650 patients.

    Diabetes Therapy. June 2014;5(1):127-40





Back to list

Search this site

Insulin Management Programme

The Progress in Insulin Management Resource Centre is a global, online educational platform created to help healthcare professionals and diabetes specialists to optimize their management of patients with type 1 and type 2 diabetes. Its key features include a free, online educational program on insulin management (10 courses in 3 content areas), selected and commented articles, summaries, infographics, webcasts, interviews, and e-learning modules.

You can register for free, start as many courses as you want simultaneously and get a certificate after course completion.

A1chieve Resource Centre Expert Panel

  • Philip Home

    Professor Philip Home

    Philip Home is Professor of Diabetes Medicine at Newcastle University and consultant physician in Newcastle, UK. Professor Home is Chairman of A1chieve® Global Advisory Board.

    Read more »

A1chieve results from bangladesh and ASEAN countries

Now available in the Resource Centre, the just published supplement to Diabetes Research and Clin...

Read more »